FOLD News and Press, Amicus Therapeutics Inc. From 05/29/19

CRANBURY, N.J., May 29, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced it has commenced a $150 million underwritten public offering of its common stock.  J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and SVB Leerink LLC are acting as joint book-ru...

Amicus Therapeutics (NASDAQ: FOLD ) announces a major expansion of its collaboration with the Perelman School of Medicine at the University of Pennsylvania aimed at the research and development of gene therapies for lysosomal disorders and 12 additional rare diseases. More news on: Amicu...

Exclusive Disease-Specific Worldwide Rights to Penn’s Next Generation Gene Therapy Technologies from the Wilson Lab for the Majority of Lysosomal Disorders              Current Collaboration Extended to Include Three...

Amicus Therapeutics ( FOLD ) missed Q1 2019 revenue estimates by $3.8 million, but the underlying growth trends for Galafold look very strong. The revenue miss was driven by currency headwinds and ordering patterns. A similar situation happened in Q3 2018 and management noted on the earnin...

CRANBURY, N.J., May 13, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced the election and appointment of Burke W. Whitman to its Board of Directors, effective at the end of this quarter. Mr. Whitman is a proven leader of corporate and military organizations. ...

CRANBURY, N.J., May 10, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a fireside chat at the Bank of America Merrill Lynch 2019 Health Care Conference in Las Vegas, NV on Tuesday, M...

It is my observation that those who sell such stocks to wait for a more suitable time to buy back these same shares seldom attain their objective. They usually wait for a decline to be bigger than it actually turns out to be. - The Patriarch of Growth Investing (Phillip Fisher) Since I rec...

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2019 Earnings Conference Call May 8, 2019 8:30 AM ET Company Participants Sara Pellegrino - Vice President of Investor Relations and Corporate Communication John Crowley - Chairman and Chief Executive Officer Bradley Campbell - Preside...

The following slide deck was published by Amicus Therapeutics, Inc. in conjunction with their 2019 Q1 earnings Read more ...

Amicus Therapeutics ( FOLD ) Q1 results : Revenues: $34.1M (+104.2%). More news on: Amicus Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...